Automated Insulin for Management of Intrapartum Glycemia
Launched by UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · Mar 12, 2025
Trial Information
Current as of April 22, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Known diagnosis of type 1 diabetes ≥ 1 year
- • Current use of commercially available AID system ≥ 6 months
- • Currently pregnant at ≥ 34 weeks
- • Singleton pregnancy
- • English- or Spanish-speaking
- Exclusion Criteria:
- • Planned cesarean delivery
- • Use of medications known to interfere with glucose metabolism
- • Intrauterine fetal demise
- • Physical or psychological disease likely to interfere with the conduct of the study and/or the ability to participate in own healthcare
Trial Officials
Ivonne Verduzco, MD
Principal Investigator
University of California, San Francisco
About University Of California, San Francisco
The University of California, San Francisco (UCSF) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a focus on translating scientific discoveries into effective therapies, UCSF collaborates with a diverse array of stakeholders, including healthcare professionals, industry partners, and patient communities. The university's research programs emphasize interdisciplinary approaches and leverage cutting-edge technology to address complex medical challenges. As a sponsor of clinical trials, UCSF is dedicated to maintaining the highest standards of ethical conduct and scientific rigor, ensuring the safety and well-being of participants while contributing to the broader medical knowledge base.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Francisco, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Related Blog Entries
View all
